Valerie Chrosniak
Adult Health · Alexandria, VANPI 1982666590
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations.
Across 201 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$662
- Novo Nordisk$570
- Pfizer$546
- Lilly USA, LLC$532
- AstraZeneca$334
- Bayer$302
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,527100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $662 |
| Novo Nordisk | 30 | $570 |
| Pfizer | 25 | $546 |
| Lilly USA, LLC | 23 | $532 |
| AstraZeneca | 12 | $334 |
| Bayer | 10 | $302 |
| Amgen(2 entities) | 10 | $233 |
| Boehringer Ingelheim | 7 | $196 |
| Astellas Pharma US Inc | 7 | $175 |
| Exact Sciences | 6 | $167 |
| Medtronic | 2 | $127 |
| Abbott | 4 | $80 |
| Merck | 4 | $77 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Novartis | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Johnson & Johnson | 3 | $46 |
| GSK | 3 | $43 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Lundbeck LLC | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Medicomp Inc | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Cumberland Pharmaceuticals, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Optinose US, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,527 in reported general payments places this provider in the 85th percentile of 368 adult health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 71 | $62,759 |
| JanuviaSitagliptin Phosphate | 23 | $23,698 |
| FarxigaDapagliflozin Propanediol | 16 | $15,813 |
| EliquisApixaban | 15 | $15,422 |
| EntrestoSacubitril/Valsartan | 12 | $8,550 |
| MyrbetriqMirabegron | 14 | $7,863 |
| VascepaIcosapent Ethyl | 14 | $7,819 |
| Esomeprazole Magnesium | 14 | $2,979 |
| Fluticasone Propionate | 151 | $2,804 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,721 |
| PradaxaDabigatran Etexilate Mesylate | 12 | $2,387 |
| Atorvastatin Calcium | 263 | $2,298 |
| Levothyroxine Sodium | 158 | $1,955 |
| Lidocaine | 21 | $1,955 |
| Levetiracetam | 32 | $1,739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Pradaxa | $196 | $65,14783 claims |
| MerckJanuvia | $77 | $23,69823 claims |
| AstraZenecaFarxiga | $334 | $15,81316 claims |
| PfizerEliquis | $546 | $15,42215 claims |
| NovartisEntresto | $51 | $8,55012 claims |
| Astellas Pharma US IncMyrbetriq | $175 | $7,86314 claims |
| AbbVieSynthroid | $662 | $78215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 368 adult health providers in Virginia.
Other adult health in Alexandria
- Julia CamargoAlexandria$8K
- Robin KorinAlexandria$6K
- Amanda LawtonAlexandria$5K
- Ashley LoweAlexandria$4K
- Kerry McGonagleAlexandria$4K
- Christine KesslerFort Belvoir$107K
- Denise BruenCharlottesville$45K
- Theresa Harrington StukusFairfax$40K
- Chelsea KoskovichFredericksburg$34K
- Brittany BrownLynchburg$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.